AICAR: Comprehensive Research Overview

Document Version: 1.0 Last Updated: December 2024 Classification: Research Paper - Metabolic Modulators

Goal Relevance:

• Boost endurance and stamina without needing to exercise
• Enhance muscle recovery and performance for athletic training
• Support weight loss and fat burning by mimicking exercise effects
• Improve energy levels and reduce fatigue for better daily performance
• Assist in managing blood sugar levels for those with type 2 diabetes
• Promote heart health by potentially reducing cardiac risks during surgery
• Aid in metabolic health and improve glucose uptake in muscles

1. Executive Summary

Overview

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), also known as AICA riboside or acadesine, is a nucleoside analog that serves as an intermediate in purine biosynthesis. With the molecular formula C₉H₁₅N₄O₈P and molecular weight of 338.21 g/mol, AICAR has gained significant attention in metabolic and cardiovascular research for its ability to activate AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis.

AMPK Activation Mechanism

Inside cells, AICAR is converted into ZMP (AICAR monophosphate), which structurally resembles AMP:

1. Cellular Uptake: AICAR enters cells via adenosine transporters
2. Phosphorylation: Adenosine kinases convert AICAR → ZMP
3. AMPK Activation: ZMP mimics AMP, causing:
   • Direct allosteric activation of AMPK
   • Promotion of AMPK phosphorylation by upstream kinases
4. Metabolic Reprogramming: Activated AMPK triggers catabolic pathways (fatty acid oxidation, glucose uptake) and inhibits anabolic pathways (lipogenesis, protein synthesis)

Critical Distinction: Unlike existing AMPK activation methods, AICAR does not perturb cellular ATP, ADP, or AMP levels, making it a useful research tool.

"Exercise Mimetic" Effects

The most striking finding: even in sedentary mice, 4 weeks of AICAR treatment induced metabolic genes and enhanced running endurance by 44%:

• Fiber Type Switching: AICAR induced fatigue-resistant Type I (slow-twitch) fiber specification
• Metabolic Reprogramming: Increased expression of genes involved in fatty acid oxidation and mitochondrial biogenesis
• PPARδ Dependence: Endurance enhancement associated with activation of both AMPK and PPARδ

Implication: AICAR can partially replicate exercise benefits without physical activity, hence the term "exercise-in-a-pill" or "exercise mimetic."

Clinical Investigation History

Cardiovascular Applications:

AICAR infusion improved postischemic recovery in the heart in 1980s animal studies, prompting human trials:

• Target: Reduce cardiac ischemia during coronary artery bypass graft (CABG) surgery and post-MI
• Early Promise: 1997 meta-analysis showed AICAR reduced early cardiac death, MI, and combined adverse CV outcomes
• Later Disappointment: Promising meta-analysis results NOT confirmed by subsequent larger clinical trials
• Current Status: No FDA approval for cardiovascular indications

Diabetes Research:

Systemic AICAR administration in humans reduced hepatic glucose output and increased skeletal muscle glucose uptake:

• Clinical Trial: Patients with type 2 diabetes treated with AICAR (45 mg/kg/hr IV) showed significant decrease in glucose production
• Limitation: Very poor oral bioavailability; continuous IV infusion required → unsuitable for chronic metabolic disorder treatment

AMPK-Independent Effects

There is increasing evidence that numerous AICAR effects, previously attributed to AMPK activation, are AMPK-independent:

• ZMP accumulation may affect other cellular pathways beyond AMPK
• Direct effects on purine metabolism and one-carbon metabolism
• Off-target effects complicate interpretation of "AMPK" studies using AICAR

Safety and Regulatory Status

WADA Ban:

AICAR appeared on WADA Prohibited List due to performance-enhancing potential:

• Classified as metabolic modulator and gene doping
• Banned at all times (in- and out-of-competition)
• Detection methods developed for urine and blood testing

Safety Concerns:

• Cardiotoxicity at high doses
• Acute renal failure, liver complications, hyperkalemia at 1 mg/g BW in rats
• Short half-life and poor oral bioavailability
• Lack of long-term human safety data

Evidence Quality

• AMPK Activation (Preclinical): HIGH - Robust mechanistic data
• Exercise Mimetic Effects (Animals): HIGH - Well-characterized in rodents
• Cardiovascular Protection (Humans): MODERATE - Mixed clinical trial results
• Diabetes (Humans): MODERATE - Demonstrated efficacy but impractical route of administration
• Human Performance Enhancement: LOW - No controlled human trials (unethical due to WADA ban)
• Long-Term Safety: LOW - Insufficient human data

2. Chemical Structure & Composition

Chemical Name: 5-Aminoimidazole-4-carboxamide ribonucleoside Alternate Names: AICA riboside, Acadesine, ZMP precursor Molecular Formula: C₉H₁₅N₄O₈P (as ribonucleotide, ZMP); C₉H₁₄N₄O₅ (as riboside, AICAR) Molecular Weight: 338.21 g/mol (ZMP); 258.23 g/mol (AICAR) CAS Number: 3031-94-5 (ZMP); 2627-69-2 (AICAR) PubChem CID: 65110 (AICAR)

Structural Features

AICAR consists of:

1. Imidazole ring: 5-amino-4-carboxamide substituted imidazole
2. Ribose sugar: β-D-ribofuranose (5-carbon sugar)
3. Glycosidic bond: N-glycosidic linkage between imidazole and ribose

Phosphorylation:

• AICAR (riboside) → ZMP (ribonucleotide) via adenosine kinase
• ZMP contains 5'-monophosphate group attached to ribose

Relationship to Purine Metabolism

AICAR is an intermediate in de novo purine biosynthesis:

• Precursor to inosine monophosphate (IMP)
• IMP → AMP or GMP (adenine/guanine nucleotides)
• Accumulation of AICAR/ZMP signals purine depletion → activates AMPK

3. Mechanism of Action

AMPK Activation via ZMP

AICAR is phosphorylated to ZMP, which mimics AMP's activating effects on AMPK:

AMPK Structure:

• Heterotrimeric complex: α (catalytic), β (scaffolding), γ (regulatory) subunits
• γ subunit contains AMP/ATP/ADP binding sites (CBS domains)

ZMP Mechanism:

1. Allosteric Activation: ZMP binds γ subunit → conformational change → increased α subunit catalytic activity
2. Phosphorylation Promotion: ZMP binding protects Thr172 (α subunit activation loop) from dephosphorylation
3. Upstream Kinase Activation: Enhances LKB1-mediated phosphorylation of Thr172

Result: AICAR increases phosphorylation of AMPK α subunit and acetyl-CoA carboxylase (ACC), confirming AMPK activation.

Metabolic Effects of AMPK Activation

Catabolic Pathway Activation:

1. Fatty Acid Oxidation: AMPK phosphorylates ACC → inhibits ACC → reduced malonyl-CoA → CPT1 disinhibition → increased β-oxidation
2. Glucose Uptake: AMPK promotes GLUT4 translocation to plasma membrane (insulin-independent)
3. Glycolysis: AMPK activates phosphofructokinase-2 → increased fructose-2,6-bisphosphate → glycolysis stimulation
4. Mitochondrial Biogenesis: AMPK activates PGC-1α → mitochondrial gene expression

Anabolic Pathway Inhibition:

1. Lipogenesis: ACC inhibition → reduced fatty acid synthesis
2. Protein Synthesis: AMPK inhibits mTOR → decreased protein translation
3. Cholesterol Synthesis: AMPK phosphorylates HMG-CoA reductase → inhibition

Exercise Mimetic Mechanism

AICAR induces metabolic genes and enhances endurance via PPARδ-dependent manner:

1. AMPK Activation: AICAR → ZMP → AMPK phosphorylation
2. PPARδ Activation: AMPK → PGC-1α → PPARδ coactivation
3. Gene Expression:
   • Oxidative muscle fiber genes (Type I specification)
   • Mitochondrial enzymes (fatty acid oxidation)
   • Uncoupling proteins (UCP3)
4. Fiber Type Switching: Fast-twitch (Type II) → Slow-twitch (Type I) over weeks of treatment

Synergy with GW501516:

Researchers stacked GW501516 (PPARδ agonist) with AICAR and discovered this combination activated 40% of genes turned on when mice exercised:

• GW501516 directly activates PPARδ
• AICAR activates AMPK → indirect PPARδ activation
• Combined effect greater than either alone

AMPK-Independent Effects

Numerous AICAR effects are AMPK-independent:

ZMP as Signaling Molecule:

• ZMP is a master regulator of one-carbon metabolism
• Regulates purine biosynthesis enzymes
• Affects folate metabolism and nucleotide pools

Direct Cellular Effects:

• Apoptosis induction in lymphoblastic leukemia cells (AMPK-independent)
• Inhibition of specific signaling pathways unrelated to AMPK

4. Pharmacokinetics and Metabolism

Absorption:

• Oral Bioavailability: Very poor; AICAR has ribose structure → high polarity → minimal GI absorption
• IV Infusion: Preferred route in clinical trials (continuous infusion for hours)
• Subcutaneous: Used in research settings; slower absorption vs. IV

Distribution:

• AICAR rapidly taken up by erythrocytes and phosphorylated to ZMP
• Tissue distribution: Primarily muscle and liver (high adenosine transporter expression)
• Cannot cross blood-brain barrier effectively due to high polarity

Metabolism:

1. Phosphorylation: Adenosine kinase converts AICAR → ZMP (active metabolite)
2. ZMP Metabolism: ZMP → inosine monophosphate (IMP) via AICAR transformylase in purine pathway
3. IMP Fate: IMP → AMP or GMP (normal purine metabolism)

Elimination:

• Half-Life: Short; high polarity and rapid metabolism (specific values not well-documented)
• Clearance: Renal excretion; metabolized via purine pathway

Pharmacokinetic Challenges:

• Poor oral bioavailability → IV required
• Short half-life → continuous infusion needed
• Limited CNS penetration → primarily peripheral effects

5. Dosing Protocols and Administration

Clinical Trial Dosing (IV Infusion):

Phase 2/3 trials employed continuous IV infusion for up to 7 hours:

• Dose Range: 5-315 mg/kg
• Typical Dose: 45 mg/kg/hr for diabetes trials
• Duration: Single infusion or repeated infusions over days
• Route: Intravenous (IV) only in clinical trials

Research/Preclinical Dosing (Subcutaneous):

AICAR administered subcutaneously at 500 mg/kg 3 days/week in animal studies:

• Dissolved in DMSO (5%)/alcohol (5%)/saline (90%)
• Monday, Wednesday, Friday dosing schedule
• Duration: Weeks to months

Black Market/Unapproved Use (NOT RECOMMENDED):

Research dosing ranges from 1,000-3,000 mcg once daily:

• Starting Dose: 25 mg daily (conservative)
• Duration: Maximum 14 days; 1-2 month washout before re-cycling
• Route: Subcutaneous injection
• WARNING: No approved human protocols; significant safety risks

Combination with GW501516:

One protocol uses 10 mg AICAR daily + 5 mg GW501516:

• Claimed synergistic endurance enhancement
• Both substances WADA-banned
• No human safety data for combination

Body Weight-Based Dosing Protocol (SOP)

Step 1: Assess Risk Factors

Absolute Contraindications:

• Pre-existing kidney disease or impaired renal function (eGFR <60)
• Active liver disease or elevated liver enzymes
• Gout or hyperuricemia (AICAR increases uric acid)
• Pregnancy, breastfeeding, or under 18 years
• Competitive athletes (WADA banned substance)

Relative Contraindications:

• Diabetes (hypoglycemia risk with AMPK activation)
• Current use of nephrotoxic medications
• Cardiovascular conditions (limited safety data)

Step 2: Calculate Starting Dose by Body Weight

Note: Clinical IV trials used 45 mg/kg/hr infusions - these are NOT applicable to subcutaneous use. Subcutaneous bioavailability and safety profile differ significantly.

Step 3: Select Dosing Protocol

Step 4: Titration Schedule

CRITICAL: Do NOT exceed 14 consecutive days without a break. Never exceed 50 mg/day without medical supervision.

Step 5: Cycling Schedule (MANDATORY)

Step 6: Combination Protocols (Research Only)

AICAR + GW501516 Stack (Both WADA Banned):

• AICAR: 25-50 mg daily
• GW501516: 10-20 mg daily (oral)
• Duration: 14 days maximum
• Claimed effect: 40% of exercise-induced genes activated
• Risk: Unknown long-term safety; both are experimental compounds

AICAR + Exercise:

• Lower doses (25-50 mg) with moderate cardio
• Inject 30-60 minutes pre-exercise
• May enhance fat oxidation during exercise

Step 7: Required Monitoring

Before Starting:

• Baseline kidney function (BUN, creatinine, eGFR)
• Liver enzymes (ALT, AST)
• Uric acid level
• Fasting glucose

During Cycle:

• Weekly kidney function tests (minimum)
• Monitor urine output and color
• Daily hydration tracking (minimum 3L water/day)

Stop Immediately If:

• Decreased urine output
• Dark/cola-colored urine
• Flank pain or kidney area discomfort
• Severe fatigue or weakness
• Signs of hypoglycemia (confusion, shakiness, sweating)

Step 8: Reconstitution and Administration

Reconstitution:

• 50 mg vial + 2 mL bacteriostatic water = 25 mg/mL
• Gently swirl (do not shake)
• Refrigerate after reconstitution; use within 30 days

Injection Sites:

• Subcutaneous: Abdomen, outer thigh, upper arm
• Rotate injection sites daily
• Use 29-31 gauge insulin syringes

Timing:

• Best: 30-60 minutes before exercise (if combining with activity)
• Alternative: Morning on empty stomach
• Can split daily dose into AM/PM if >50 mg total

6. Clinical Research & Evidence

Cardiovascular Trials:

1997 meta-analysis: AICAR reduced early cardiac death, MI, and combined adverse CV outcomes:

• Indication: CABG surgery ischemia protection
• Result: Initial promise NOT confirmed in larger trials
• Conclusion: AICAR not approved for cardiovascular use

Diabetes Trial:

Type 2 diabetes patients treated with AICAR (45 mg/kg/hr IV) showed significant decrease in glucose production:

• Mechanism: Reduced hepatic glucose output; increased muscle glucose uptake
• Limitation: IV infusion impractical for chronic diabetes management

Exercise Mimetic (Preclinical):

4 weeks AICAR in sedentary mice enhanced running endurance by 44%:

• Metabolic gene expression increased
• Type I fiber specification induced
• No human trials (unethical due to WADA ban)

7. Safety Profile and Adverse Events

Cardiotoxicity:

Safety concerns include cardiotoxicity at high doses in research settings

Renal/Hepatic Toxicity:

High doses (1 mg/g BW) in rats caused acute renal failure, liver complications, hyperkalemia, oliguria, uremia

B-Cell Lymphoma:

AICAR induced apoptosis in childhood ALL cell lines and B-cells from lymphoma patients; role of AMPK not fully investigated

Long-Term Safety:

Lack of comprehensive long-term human safety data makes unmonitored use risky

11. Product Cross-Reference

Core Peptides page returned corrupted content. AICAR available from research suppliers at $100-300 per 50-100 mg; research use only; not for human consumption.

12. References & Citations

1. AICA ribonucleotide - Wikipedia
2. AICAr AMPK Activator Systematic Review - PMC
3. AMPK and PPARδ Agonists Are Exercise Mimetics - PMC
4. 5-aminoimidazole-4-carboxamide ribonucleoside activating AMPK - PubMed
5. What Athletes Should Know About AICAR - USADA
6. AICAR Dosage Calculator
7. Administration of AICAR Prevents Diabetic Polyneuropathy - MDPI
8. ZMP: Master Regulator of One-Carbon Metabolism - PMC
9. GW-501516 and AICAR Peptides - EliteFitness
10. AICAR Scientific Overview - BC9

Document Prepared By: Research Team, Epiq Aminos Intended Use: Educational and research reference Disclaimer: AICAR is not FDA-approved, WADA-banned, and associated with significant safety risks. For research purposes only.